In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...
Overall, 44.7% of the ARB initiators were continuously persistent to their original drug class at 3 years. HealthDay News — For patients with hypertension, initiating treatment with an angiotensin ...
A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.
Getting Covid could increase your risk of developing pulmonary hypertension, a deadly blood pressure condition. In a new study published in Scientific Reports, researchers found that people who ...
A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results